The COVID-19 vaccines are likely to become available for children up to six month old this summer.
A third pediatric dose of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years of age has shown a strong immune response raising such a possibility.
Both Moderna and Pfizer-BioNTech are pushing ahead with plans to vaccinate younger age groups.
RELATED STORY:
The Pfizer-BioNTech vaccine remains available to children over 12-years of age and for children aged 5 and above it has become available since February in the UAE.
Earlier trials were delayed due to Omicron strain which caused a surge in cases requiring hospital treatment in children in some countries which included the US.
READ ON:
Moderna has submitted data to the US Food and Drug Administration and it has shown that the vaccine was about 51 per cent effective against children under 2 and 37 per cent for children between 2 to 5.
Also, this week, Pfizer will share its data with the FDA on a trial for three doses of a vaccine for children aged 6 months to 4 years of age.
